BioSpace News Archive

BioAxone BioSciences, Inc., a biotechnology company applying an innovative understanding of axon regeneration and neuronal signaling to transform the lives of patients afflicted with neurotrauma or neurovascular disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO).

Integral Molecular has expanded its partnership with Funakoshi, a leader in distributing life science research reagents and services, to be the exclusive provider of Integral Molecular’s therapeutic antibody characterization technologies in Japan.

QurAlis Corporation, a biotech company developing breakthrough precision medicines for ALS and other genetically validated neurodegenerative diseases, today announced the publication of an article in Cell Reports titled Human Amyotrophic Lateral Sclerosis Excitability Phenotype Screen: Target Discovery and Validation

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced positive new data and program updates for its development pipeline of PATrOL-enabled genetic medicines.

Verista, a leading consulting firm focused on compliance services primarily to the pharmaceutical and biotech industries, announced a collaborative partnership with INCOG BioPharma Services, a newly formed Contract Development and Manufacturing Organization also based in Fishers, Indiana.

Health Canada has completed a safety review confirming that the use of non-steroid anti-inflammatory drugs —such as acetylsalicylic acid, ibuprofen, naproxen, diclofenac and celecoxib —starting from approximately 20 weeks of pregnancy or later, may cause rare but serious kidney problems in an unborn baby.

Results to be presented at 2021 ASCO Annual Meeting demonstrate that Abemaciclib and LY3214996 achieve pharmacologically-relevant concentrations in Gd-non-enhancing GBM tissue.

Onward Therapeutics and Institut du Cancer de Montpellier announced the execution of an exclusive collaboration and worldwide option and license agreement based on a research program in onco-metabolism being conducted by ICM, Montpellier, France.

THR-149 is a potent plasma kallikrein inhibitor for the treatment of DME in the roughly 40% of the patient population respondingsuboptimally to anti-VEGF therapy

Polyphor AG announced that it will host a key opinion leader roundtable on Covid-19, the need for novel therapies for severe infections and the potential role of balixafortide, a selective CXCR4 antagonist, on Thursday, June 10, 2021 at 8am Eastern Time/2pm Central European Time.